CAMP response element-binding protein (CREB)-regulated transcription coactivator 1 (CRTC1) plays an important role in synaptic plasticity, learning, and long-term memory formation through the regulation of neuronal activity-dependent gene expression, and CRTC1 dysregulation is implicated in Alzheimer’s disease (AD). Here, we show that increased S-nitrosylation of CRTC1 (forming SNO-CRTC1), as seen in cell-based, animal-based, and human-induced pluripotent stem cell (hiPSC)-derived cerebrocortical neuron-based AD models, disrupts its binding with CREB and diminishes the activity-dependent gene expression mediated by the CRTC1/CREB pathway. We identified Cys216 of CRTC1 as the primary target of S-nitrosylation by nitric oxide (NO)-related species. Using CRISPR/Cas9 techniques, we mutated Cys216 to Ala in hiPSC-derived cerebrocortical neurons bearing one allele of the APP Swe mutation (AD-hiPSC neurons). Introduction of this nonnitrosylatable CRTC1 mutant rescued defects in AD-hiPSC neurons, including decreased neurite length and increased neuronal cell death. Additionally, expression of nonnitrosylatable CRTC1 in vivo in the hippocampus rescued synaptic plasticity in the form of long-term potentiation in 5XFAD mice. Taken together, these results demonstrate that formation of SNO-CRTC1 contributes to the pathogenesis of AD by attenuating the neuronal activity-dependent CREB transcriptional pathway, and suggests a therapeutic target for AD.
Background/Objectives: Genomic profiling has become central to understanding prognosis in pancreatic ductal adenocarcinoma (PDAC), yet the canonical drivers KRAS, TP53, SMAD4, and CDKN2A do not fully explain survival heterogeneity, and the prognostic impact of co-occurring alterations remains incompletely characterized. Methods: We performed integrated genomic, transcriptomic, proteomic, phosphoproteomic, and immune deconvolution analyses of publicly available PDAC datasets. Un-supervised clustering of survival extremes in MSK-IMPACT identified a subgroup enriched for concurrent TP53 and ARID1A mutations. Results: ARID1A was mutated in 7–8% of tumors across cohorts, of which 66–72% were TP53 co-mutated. Co-mutated tumors had the shortest overall survival of any subgroup (median 21.4 vs. 34.8 months in non-co-mutated tumors; log-rank p < 0.001), a pattern that persisted in the full MSK-IMPACT cohort and in independent multi-cohort validation. Transcriptomic analysis showed enrichment of MYC target, EMT, and E2F/cell-cycle programs alongside coordinated suppression of oxidative phosphorylation and lipid metabolism, with EMT tracking more closely with ARID1A mutation and cell-cycle programs with TP53 mutation. Immune deconvolution identified reduced plasma cell infiltration in co-mutated tumors. Proteomic profiling recapitulated EMT, hypoxia, and TNF-α/NF-κB enrichment, and kinase-substrate enrichment analysis inferred increased mTOR and MEK1 activity. Conclusions: These findings are hypothesis-generating and suggest that TP53 + ARID1A co-mutated PDAC represents a prognostically distinct subtype, with candidate therapeutic vulnerabilities in MAPK, mTOR, and proteostasis pathways that warrant validation in larger cohorts and functional studies.